Appointment of Non-Executive Director

RNS Number : 9148O

Cambridge Cognition Holdings PLC

02 June 2015

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Appointment of Non-Executive Director

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces  that Dr. Andy Blackwell will step down as an Executive Director but will remain on the Board as a Non-Executive Director with effect from the 1 July 2015.

Andy joined the Company in 2006 and was appointed as a Director and CSO in 2007. Andy helped the Company list on AIM in April 2013 and assisted in the completion of the new strategic plan which is now being implemented. Andy has led the scientific commercial development activities and built the scientific team that has established Cantab as the number one in computerised cognition technology.

In his role as NED Andy will continue to support the company's world-class scientific teams in the EU and USA. As a result of this change Andy will be able to pursue other opportunities and at the same time, Cambridge Cognition will still benefit from the key relationships Andy holds with the scientific and technology community, industry partners and patient advocacy groups.  

Nick Kerton, Chief Executive Officer, of Cambridge Cognition said: "The Board fully supports Andy's professional development plans and appreciates the new perspectives in science and medical technology that he will continue to bring to the Company as part of his ongoing NED role."   

Enquiries:

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Geoff Nash/Simon Hicks		(Corporate Finance)
Malar Velaigam	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic  scientists  in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function.  In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing.  Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

 

END

 

 

BOAGIGDLRDGBGUD